Erik Amble

JenaValve Technology GmbH develops and manufactures transcatheter valve implantation systems for transapical and transfemoral implantation. The firm offers a therapeutic alternative to surgical aortic valve replacement for high-risk patients suffering from aortic heart valve stenosis. The company was founded by Markus Ferrari, Volker Guyenot and Hans-Reiner Figulla in 2006 and is headquartered in Munich, Germany.

Alertis Medical AS was established in 2000 to develop and commercialize a unique technology for the early detection of critical conditions related to blood supply and respiration, addressing considerable unmet needs in medicine. The patented technology originates from the anesthesiologist Prof T. I. Tønnessen, MD, PhD, and the physicist P. Mirtaheri, PhD, at Rikshospitalet University Hospital, Oslo

Vessix Vascular, Inc. develops products to treat artery disease. The company was founded in 2003 and is headquartered in Laguna Hills, CA.

Sequana Medical AG operates as a medical device company. It specializes in the production and design of implantable pump systems to manage fluid balance within the body. The firm offers the Alfapump system, its proprietary solution to manage and remove ascites, which can occur as a symptom of liver disease, cancer, or congestive heart failure and its focus areas encompass clinical research, product innovation, and technology development. The company was founded by Noel L. Johnson in 2000 and is headquartered in Zurich, Switzerland.

Glenwood Management develops, owns, manages, and rents apartments. The private company is based in New York, NY and has subsidiaries in the United States.

JenaValve Technology, Inc. designs, develops, manufactures, and markets transcatheter aortic valve replacement systems. The company was founded on March 27, 2006 and is headquartered in Wilmington, DE.

Omega Fund Management Ltd. (OFM) is the wholly-owned private equity firm founded by Dr. Otello Stampacchia in 2004. The firm is headquartered in the US.

Corflow Therapeutics AG is a company based in Switzerland that is developing proprietary technologies to measure the coronary microvascular status and provide therapy to the compromised coronary microcirculation at the same time in the catheter laboratory. The Swiss company's focus is on treating microvascular obstruction (MVO) after an acute heart attack, which is documented to be an independent marker leading to costly complications such as heart failure. Corflow's technologies may enable interventional cardiologists to treat MVO in severe heart attack patients, thereby potentially reducing the short- and long-term complication rates in these patients. The company was founded in 2016 by Martin T. Rothman and Robert S. Schwartz.

Serca Pharmaceuticals AS develops, markets, and sells drug treatment products, medicinal products, and equipment for injuries. The company was founded on October 8, 2018 and is headquartered in Lysaker, Norway.